uniQure N.V. announced a Type A meeting with the FDA to discuss the data package for accelerated approval of AMT-130, a gene therapy for Huntington’s disease. CEO Matt Kapusta highlighted the urgent need for disease-modifying therapies. The company plans to update on regulatory progress after the meeting. uniQure focuses on gene therapy for severe diseases and has successfully developed a treatment for hemophilia B. Forward-looking statements indicate the company’s commitment to advancing gene therapies and addressing regulatory challenges. Investors are advised to consider risks and uncertainties outlined in the company’s SEC filings.

Read more at GlobeNewswire: uniQure Announces Type A Meeting Scheduled with FDA